Immunic Inc To Discuss IMU-856 Clinical Phase 1b Results in Celiac Disease Call Transcript
Good morning, everybody. I would like to welcome you to the Immunic's webcast to present the positive results from our Phase Ib clinical trial of IMU-856, in celiac disease patients reported this morning. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic. I will also be the moderator on today's webcast.
Speaking on the call are Dr. Daniel Vitt, our Chief Executive Officer and President; and Dr. Andreas Muehler, our Chief Medical Officer. (Operator Instructions) This event is being recorded. (Operator Instructions)
Before we begin, I would like to remind you that this presentation may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, estimate or words with similar meaning, and such statements involve a number of risks and uncertainties that could cause Immunic's actual results to differ materially from those discussed here.
Please note that these forward-looking statements reflect Immunic's opinions only as of the date
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
